Amarin reported $224M in Stock for its fiscal quarter ending in September of 2024.


Stock Change Date
AbbVie USD 4.53B 345M Mar/2025
Alnylam Pharmaceuticals USD 71.69M 6.11M Jun/2025
Amarin USD 224M 15.41M Sep/2024
AstraZeneca USD 6.47B 583M Jun/2025
GlaxoSmithKline GBP 6.07B 72M Jun/2025
Halozyme Therapeutics USD 181.5M 16.64M Jun/2025
Ionis Pharmaceuticals USD 8.48M 3.02M Jun/2025
Neurocrine Biosciences USD 56.9M 2.2M Jun/2025
Novartis USD 6.31B 478M Jun/2025